Pacira BioSciences (PCRX) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pacira BioSciences (PCRX) has outperformed Savara (SVRA) over the past year, gaining 57.5% versus a gain of 39.2%. Over five years, SVRA leads with a +274.4% price change compared with -31.7% for PCRX. Pacira BioSciences is the larger company by market cap ($1.45 billion vs $1.01 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PCRX | SVRA |
|---|---|---|
| Share price | $36.31 | $4.92 |
| Market cap | $1.45B | $1.01B |
| 1-day change | -0.22% | +1.86% |
| YTD return | +40.30% | -19.90% |
| 1-year return | +57.46% | +39.19% |
| 5-year return | -31.75% | +274.42% |
| P/E ratio (TTM) | 103.74 | — |
| Forward P/E | 10.50 | — |
| EPS (TTM) | $0.35 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $726.41M | — |
| Revenue growth (YoY) | +3.63% | — |
| Net income (latest FY) | $7.03M | — |
| Gross margin | 79.39% | — |
| Operating margin | 2.64% | — |
| Net margin | 0.97% | — |
| 52-week high | $36.46 | $7.01 |
| 52-week low | $18.80 | $3.35 |
| Distance from 52-week high | -0.41% | -29.76% |
| Analyst consensus | buy | none |
| Avg. price target upside | -17.08% | +124.80% |
| Average volume | 1.03M | 1.83M |
| Shares outstanding | 39.91M | 205.46M |
| Employees | 825 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PCRX has outperformed SVRA by 18.3 percentage points over the past year.
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
PCRX vs SVRA FAQ
Which is bigger, Pacira BioSciences or Savara?
Pacira BioSciences (PCRX) is larger, with a market capitalization of $1.45B compared with $1.01B for Savara (SVRA).
Which stock has performed better over the past year, PCRX or SVRA?
PCRX returned +57.46% over the past 12 months, compared with +39.19% for SVRA (price return, excluding dividends). Past performance does not predict future results.
Are Pacira BioSciences and Savara in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.